Shutting down the ALK-1 receptor inhibits the VEGF pathway. Response seen in patients who had used antiangiogenic therapy. VEGF therapies might work best in combination. SAN FRANCISCO — Despite the widespread use of current antiangiogenic cancer therapies, many tumors escape this blockade, which...
Sun, Nov 13 2011
Filed under: Filed under: Press Releases, Research, Treatment, Conference, Cancer, Media Materials, AACR, American Association for Cancer Research, meeting, National Cancer Institute, NCI, tumor suppressor, angiogenesis, Molecular Targets, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Cancer Therapeutics, EORTC, metastasis, European Organisation for Research and Treatment of Cancer, Dr. Filippo de Braud, antiangiogenesis, monoclonal antibody, VEGF therapy